Experience of the use of tobramycin for inhalation in children with cystic fibrosis

1. Doringet G. et al. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. Journal of Cystic Fibrosis. 2004; 3:67– 91.

2. ECFS consensus on inhaled antibiotics July 22, 2008.

3. Ratjen F. et al. Inhaled tobramycin nebulizer solution for treatment of early Pseudomonas aeruginosa infection: the ELITE study 31st European Cystic Fibrosis Conference, Prague, 11–14 June 2008.

4. Ramsey B. et al. Safety and efficacy of tobramycin-solution for inhalation in patients with cystic fibrosis. Pediatr. Pulmonol. Suppl. 1997; 14: 137–138.

5. Ramsey B. et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 1999; 340: 23–30.

6. Семыкин С.Ю. и др. Проблемы и перспективы антибактериальной терапии хронической синегнойной инфекции у пациентов с муковисцидозом. Вопросы современной педиатрии. 2010; (2):94-98.

7. Капранов Н.И. и др. Опыт амбулаторного применения ингаляционных антибиотиков у пациентов с муковисцидозом и синегнойной инфекцией. Лечебное дело. 2010; 3: 35-40.

8. Cystic Fibrosis Foundation. Annual Report. 2004.

9. Kerem E. Reisman J. Corey M. et. al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med. 1992. 30;326(18):1187-91.

10. Emerson J., Rosenfeld M., McNamara S. et. al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatric Pulmonology. 2002; 34:91–100.